A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Public ClinicalTrials.gov record NCT07219602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
Study identification
- NCT ID
- NCT07219602
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Interventions
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily Drug
- Obicetrapib 10 mg Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2025 (Actual)
- Primary completion
- Mar 2028 (Estimated)
- Completion
- Jun 2028 (Estimated)
- Last update posted
- Sep 9, 2026
2025 – 2028
United States locations
- U.S. sites
- 32
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Institute of Arizona | Sun City West | Arizona | 85375 | — |
| Scripps Health - Whittier Diabetes Institute | La Jolla | California | 92037 | — |
| UC SanDiego Health | La Jolla | California | 92037 | — |
| Western University of Health Sciences | Pomona | California | 91766 | — |
| UF Health Jackson | Jacksonville | Florida | 32209 | — |
| East Coast Institute of Research LLC | Jacksonville | Florida | 32216 | — |
| East Coast Institute of Research LLC | Lake City | Florida | 32055 | — |
| K2 Medical Research | Maitland | Florida | 32751 | — |
| Floridian Clinical Research | Miami Lakes | Florida | 33016 | — |
| Cardiovascular Center of Sarasote Foundation for Research and Education | Sarasota | Florida | 34239-3513 | — |
| High Desert Heart | Meridian | Idaho | 83642 | — |
| Endeavour Health | Skokie | Illinois | 60077 | — |
| Louisville Metabolic and Atherosclerosis Research Center (L-MARC) | Louisville | Kentucky | 40213 | — |
| Eastern Maine Medical Center | Bangor | Maine | 04401 | — |
| MD Medical Research | Oxon Hill | Maryland | 20745 | — |
| Jefferson City Medical Group | Jefferson City | Missouri | 65109 | — |
| Montana Medical Research | Missoula | Montana | 59808 | — |
| Inspira Health - Internal Medicine Associates | Bridgeton | New Jersey | 08302 | — |
| Central New York Clinical Research | Manlius | New York | 13104 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Velocity Clinical Research | Durham | North Carolina | 27710 | — |
| PharmQuest Life Sciences, LLC | Greensboro | North Carolina | 27408 | — |
| Centricity Research dba Lucas Research | Morehead City | North Carolina | 28557 | — |
| Summit Research Group | Munroe Falls | Ohio | 44262 | — |
| Diabetes & Glandular Disease Clinic, P.A. | Kingsport | Tennessee | 37660 | — |
| Baylor College of Medicine - Center for Cardiometabolic Disease Prevention (The Center for Cardiovascular Disease Prevention) | Houston | Texas | 77030 | — |
| Juno Research LLC - Medical Center | Houston | Texas | 77054 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| Clinical Trials of Texas dba Flourish Research | San Antonio | Texas | 78229 | — |
| Burke Internal Medicine | Burke | Virginia | 22015-2234 | — |
| Burke International Medicine DBA Manassas Clinical Research Center | Manassas | Virginia | 20110 | — |
| Universal Research Group | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07219602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07219602 live on ClinicalTrials.gov.